Merck KGaA's Allergopharma to collaborate with S-TARget on new generation of allergy products

2 September 2014
2019_biotech_test_vial_discovery_big

Allergopharma, a division of Germany’s Merck KGaA (MRK: DE), and Austrian allergy biotechnology company S-TARget therapeutics have signed an exclusive licensing agreement.

The companies are focusing on using S-TARget’s proprietary S-TIR technology and the associated development of a new generation of products for allergies. The financial and general terms of the transaction have not been disclosed.

Allergopharma is using this collaboration as an opportunity to invest more heavily in research, and plans to develop new products for specific allergy therapeutics.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology